NEWS CENTER
sdm News
Dr. Wang delivered a keynote presentation titled "The Power of Quantitative Pharmacology: Critical Insights from Landmark Clinical Development and Regulatory Cases," providing an in-depth analysis of the central role of quantitative pharmacology across the entire clinical development lifecycle of investigational drugs.
As a clinical development pioneer with twenty years of China-focused expertise, SDM Bioservices provides comprehensive clinical research solutions to pharmaceutical partners worldwide. Our integrated capabilities include proven regulatory submission experience across China, U.S. and EU markets, innovative early-phase development approaches, reliable bioanalytical services, and demonstrated expertise in managing large-scale clinical trials for therapeutic drugs, and specialized knowledge in vaccines and medical aesthetics.
As BaoPharm's strategic regulatory partner, SDM Bioservices' global registration team delivered comprehensive support for this project, including gap analysis, technical dossier compilation, and submission management services.
KY-001 is an oral small-molecule inhibitor targeting the YAP/TAZ-TEAD interaction in the Hippo pathway with a proposed indication for advanced solid tumors driven by Hippo dysregulation.
Listen to Dr. Liping Shen: Innovating Vaccine Bioanalysis for Change
